Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dexcom (DXCM)

Dexcom adds Euan Ashley to board; board to grow to eleven directors January 1, 2026

Neutral Impact 2 of 5 leadership Written later

Dexcom appointed Stanford Chair of Medicine Dr. Euan Ashley as a director effective October 24, 2025, and he joined the Nominating and Governance and Technology Committees. The Board also confirmed that the board will increase to eleven directors effective January 1, 2026, with Jacob S. Leach's appointment as a director also taking effect that day, provided he continues to serve the company.

Key points

  • Dr. Euan Ashley appointed director effective October 24, 2025, with a term running to the 2026 annual meeting
  • Initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years
  • Annual director equity grant expected at the 2026 annual meeting with a fair value of $345,000
  • Kyle Malady steps down from the Nominating and Governance Committee but remains Technology Committee chair

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECOct 27, 2025, 4:15 PM ET
Accession number0001093557-25-000264

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.